Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Chubb
Johnson and Johnson
AstraZeneca
Harvard Business School
Express Scripts
Boehringer Ingelheim
Daiichi Sankyo
McKesson

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075509

« Back to Dashboard

NDA 075509 describes DOXAZOSIN MESYLATE, which is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Ani Pharms Inc, Apotex, Appco Pharma Llc, Dava Pharms Inc, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Mylan, Nesher Pharms, Pliva, Teva, Watson Labs Inc, Yaopharma Co Ltd, and Zydus Pharms Usa Inc, and is included in seventeen NDAs. It is available from thirty-six suppliers. Additional details are available on the DOXAZOSIN MESYLATE profile page.

The generic ingredient in DOXAZOSIN MESYLATE is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
Summary for 075509
Tradename:DOXAZOSIN MESYLATE
Applicant:Mylan
Ingredient:doxazosin mesylate
Patents:0
Therapeutic Class:Cardiovascular Agents
Genitourinary Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 075509
Mechanism of ActionAdrenergic alpha-Antagonists
Medical Subject Heading (MeSH) Categories for 075509
Suppliers and Packaging for NDA: 075509
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075509 ANDA Mylan Pharmaceuticals Inc. 0378-4021 N 0378-4021-01
DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075509 ANDA Mylan Pharmaceuticals Inc. 0378-4022 N 0378-4022-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 1MG BASE
Approval Date:Oct 19, 2000TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2MG BASE
Approval Date:Oct 19, 2000TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 4MG BASE
Approval Date:Oct 19, 2000TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Citi
US Department of Justice
Chubb
Deloitte
Covington
Colorcon
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.